ALTEOGEN Inc.

As of March 31, 2026, ALTEOGEN Inc. carries a market capitalization of 18.27T, placing it among publicly traded companies globally. Its enterprise value stands at 17.84T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ALTEOGEN Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, ALTEOGEN Inc. has 69.56M shares outstanding.

As of March 31, 2026, ALTEOGEN Inc. trades at a trailing price-to-earnings ratio of 140.20. The price-to-sales ratio is 89.58, and the price-to-book ratio stands at 36.27.

As of March 31, 2026, ALTEOGEN Inc. trades at an EV/EBITDA multiple of 192.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 87.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 209.46 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. ALTEOGEN Inc. trades at an EV/FCF ratio of 154.35, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 17.84T versus a market cap of 18.27T, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, ALTEOGEN Inc. maintains a current ratio of 2.41, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.39, indicating moderate leverage, while an interest coverage ratio of 7.28 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, ALTEOGEN Inc. posted a return on equity (ROE) of 29.86, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 13.57 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 18.87, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 30.04, useful for judging operating efficiency across full business cycles. The company generates approximately 1.29B in revenue per employee across its workforce of 157.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.31 indicates how many times ALTEOGEN Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, ALTEOGEN Inc. recorded 50.94B in income tax expense. That works out to an effective tax rate of 27.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 184.42B, leaving 130.19B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, ALTEOGEN Inc.'s stock has declined approximately 35.57% over the past 52 weeks. The 50-day moving average sits at 273,890.00, while the 200-day moving average is 281,786.54.

Over the twelve months ended March 31, 2026, ALTEOGEN Inc. generated 203.76B in revenue and converted that into 130.19B in net income, yielding earnings per share of 1,905.78. EBITDA reached 92.91B, while operating income came in at 85.18B.

As of March 31, 2026, ALTEOGEN Inc. holds 447.63B in cash and equivalents against 7.11B in total debt, resulting in a net debt position of -35.63B. Total book value stands at 503.78B, with working capital of 299.11B providing operational flexibility.

ALTEOGEN Inc. produced 149.94B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -43.58B in capital expenditures, free cash flow totaled 106.36B - equivalent to 1,530.73 per share.

Over the twelve months ended March 31, 2026, ALTEOGEN Inc. posted a gross margin of 76.57, reflecting its pricing power and cost economics. The operating margin of 41.81 and net profit margin of 63.89 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 0.58, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.01, meaning ALTEOGEN Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ALTEOGEN Inc.'s most recent stock split took place on August 5, 2026 with a 10:13 split ratio.

As of March 31, 2026, ALTEOGEN Inc. has an Altman Z-Score of 52.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.